Pfizer Inc. [NYSE: PFE] closed the trading session at $46.53 on 06/17/22. The day’s price range saw the stock hit a low of $46.28, while the highest price level was $48.03. The company report on June 20, 2022 that Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Pfizer will invest €90.5 million in Valneva.
Planned Phase 3 study confirmed to initiate in Q3 2022.
The stocks have a year to date performance of -21.20 percent and weekly performance of -6.88 percent. The stock has been moved at -24.03 percent over the last six months. The stock has performed -7.68 percent around the most recent 30 days and changed -14.64 percent over the most recent 3-months.
If compared to the average trading volume of 25.66M shares, PFE reached to a volume of 44817955 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $58.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on May 23, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on April 06, 2022, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise from $59 to $70, while BofA Securities kept a Buy rating on PFE stock. On January 03, 2022, analysts increased their price target for PFE shares from 44 to 65.
The Average True Range (ATR) for Pfizer Inc. is set at 1.45, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.88. The Price to Book ratio for the last quarter was 3.17, with the Price to Cash per share for the same quarter was set at 4.17. Price to Free Cash Flow for PFE in the course of the last twelve months was 11.59 with Quick ratio for the last quarter at 1.10.
PFE stock trade performance evaluation
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.88. With this latest performance, PFE shares dropped by -7.68% in over the last four-week period, additionally sinking by -24.03% over the last 6 months – not to mention a rise of 19.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 30.17, with the RSI for the last a single of trading hit 22.90, and the three-weeks RSI is set at 35.33 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 50.96, while it was recorded at 47.67 for the last single week of trading, and 50.18 for the last 200 days.
Pfizer Inc. [PFE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +25.58 and a Gross Margin at +57.67. Pfizer Inc.’s Net Margin is presently recorded at +27.57.
Return on Equity for this stock inclined to 31.92, with Return on Assets sitting at 13.35.
Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
Earnings per share (EPS) analysis for Pfizer Inc. [PFE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to -0.80%.
Pfizer Inc. [PFE]: Insider Ownership positions
There are presently around $176,622 million, or 69.20% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 479,065,273, which is approximately 2.964% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 408,084,122 shares of the stock with an approximate value of $18.99 billion in PFE stocks shares; and STATE STREET CORP, currently with $13.35 billion in PFE stock with ownership of nearly 0.715% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,542 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 224,463,090 shares. Additionally, 1,527 investors decreased positions by around 209,530,454 shares, while 314 investors held positions by with 3,361,875,346 shares. The mentioned changes placed institutional holdings at 3,795,868,890 shares, according to the latest SEC report filing. PFE stock had 152 new institutional investments in for a total of 16,246,962 shares, while 180 institutional investors sold positions of 49,279,625 shares during the same period.